Ultrasound features of achilles enthesitis in psoriatic arthritis: a systematic review by Patience, Aimie et al.
Ultrasound features of achilles enthesitis in psoriatic arthritis: a systematic review
Patience, Aimie; Steultjens, Martijn P.; Hendry, Gordon J.
Published in:






Publisher's PDF, also known as Version of record
Link to publication in ResearchOnline
Citation for published version (Harvard):
Patience, A, Steultjens, MP & Hendry, GJ 2021, 'Ultrasound features of achilles enthesitis in psoriatic arthritis: a
systematic review', Rheumatology Advances in Practice, vol. 5, no. Supplement 2, pp. ii19-ii34.
https://doi.org/10.1093/rap/rkab056
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 02. Jan. 2022
Systematic review
Ultrasound features of Achilles enthesitis in psoriatic
arthritis: a systematic review
Aimie Patience1, Martijn P. Steultjens1 and Gordon J. Hendry1
Abstract
Objectives The objectives were to evaluate the methodological and reporting quality of ultrasound
(US) studies of Achilles enthesitis in people with psoriatic arthritis (PsA), to identify the definitions and
scoring systems adopted and to estimate the prevalence of ultrasound features of Achilles enthesitis in
this population.
Methods A systematic literature review was conducted using the AMED, CINAHL, MEDLINE,
ProQuest and Web of Science databases. Eligible studies had to measure US features of Achilles
enthesitis in people with PsA. Methodological quality was assessed using a modified Downs and Black
Quality Index tool. US protocol reporting was assessed using a checklist informed by the European
League Against Rheumatism (EULAR) recommendations for the reporting of US studies in rheumatic
and musculoskeletal diseases.
Results Fifteen studies were included. One study was scored as high methodological quality, 9 as
moderate and 5 as low. Significant heterogeneity was observed in the prevalence, descriptions, scoring
of features and quality of US protocol reporting. Prevalence estimates (% of entheses) reported in-
cluded hypoechogenicity [mean 5.9% (S.D. 0.9)], increased thickness [mean 22.1% (S.D. 12.2)], erosions
[mean 3.3% (S.D. 2.5)], calcifications [mean 42.6% (S.D. 15.6)], enthesophytes [mean 41.3% (S.D. 15.6)]
and Doppler signal [mean 11.8% (S.D. 10.1)].
Conclusions The review highlighted significant variations in prevalence figures that could potentially
be explained by the range of definitions and scoring criteria available, but also due to the inconsistent
reporting of US protocols. Uptake of the EULAR recommendations and using the latest definitions
and validated scoring criteria would allow for a better understanding of the frequency and severity of
individual features of pathology.
Key words: psoriatic arthritis, Achilles tendon, ultrasound, enthesitis, scoring, systematic review
Introduction
Enthesitis is a hallmark feature of psoriatic arthritis (PsA)
and presents as inflammation at the site of soft tissue
insertion to bone [1]. The most common site of enthesi-
tis in PsA is the Achilles tendon insertion to the calca-
neum [2, 3]. Enthesitis can significantly limit a person’s
ability to carry out essential activities of daily living and
can impact health-related quality of life [4]. Achilles
Key messages
. There is significant variation in the reported prevalence of Achilles enthesitis ultrasound features in PsA.
. Studies should adopt up-to-date, validated definitions and scoring of ultrasound pathology at the Achilles
tendon/entheses.
. Uptake of the new EULAR recommendations should address the inconsistency in ultrasound reporting highlighted.
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enthesitis is often difficult to treat and can persist de-
spite the initiation or escalation of pharmacological man-
agement. The current recommended first-line therapies
for enthesitis in PsA are non-steroidal anti-inflammatory
drugs (NSAIDs) and physiotherapy. Persistent symptoms
may require escalation to biologic therapies (TNF inhibi-
tors, IL-12/IL-23i) and/or corticosteroid injection [5].
Ultrasound (US) is highly sensitive for assessing in-
flammation and can detect different features of enthesi-
tis including tendon thickening, hypoechogenicity,
erosions, enthesophytes and subclinical enthesitis in
people with PsA [6, 7]. Access to US imaging varies so
enthesitis diagnosis is often based on clinical assess-
ment, typically measured using the Leeds Enthesitis
Index [8]. Clinical assessment may be able to detect
swelling that could be indicative of moderate to severe
thickening of the Achilles tendon but can be difficult to
distinguish from the presence of an enlarged retrocalca-
neal bursa, hindfoot joint effusion or oedema [9]. Unlike
US, clinical assessment cannot measure pathology and
compare it to a normative value and is unlikely to be
able to assess other pathological features of enthesitis
(e.g. enthesophytes and erosion). Clinical assessment of
Achilles enthesitis in people with PsA has shown poor
correlation with US [10]. Furthermore, it is difficult to dif-
ferentiate between the pain response of fibromyalgia
(FM) and PsA-related enthesitis at entheseal sites [11].
US has shown good sensitivity and specificity for
detecting Achilles entheseal pathology in PsA and there
are a variety of US feature definitions and scoring sys-
tems available. The Glasgow Ultrasound Enthesitis
Scoring System (GUESS) [12] provides definitions of
entheseal abnormality in the lower limbs in patients with
spondyloarthropathy (SpA) (36 bilateral entheseal sites
scored present/absent, total/36 points). The Achilles
subscale of the GUESS criteria (8/36 bilateral entheseal
sites) refers to Achilles tendon thickness 5.29mm, ret-
rocalcaneal bursitis, posterior pole of calcaneus erosion
and posterior pole of calcaneus enthesophytes. The
OMERACT US Task Force defines enthesopathy as ‘ab-
normally hypoechoic (loss of normal fibrillar architecture)
and/or thickened tendon or ligament at its bony attach-
ment (may occasionally contain hyperechoic foci consis-
tent with calcification), seen in 2 perpendicular planes
that may exhibit Doppler signal and/or bony changes in-
cluding enthesophytes, erosions, or irregularity’ [13]. The
Madrid Sonographic Enthesitis Index (MASEI) offers
both binary and semi-quantitative scoring of Achilles
entheseal features and has been shown to have face va-
lidity as a diagnostic tool for patients with SpA [14]. In
an attempt to provide homogeneity in assessing and
reporting US enthesitis, a Delphi study elicited agree-
ment for the inclusion of hypoechogenicity, increased
tendon thickness, enthesophytes, calcifications, erosions
and Doppler signal 2 mm from the bony insertion as
features of enthesitis [15]. The OMERACT Ultrasound
Task Force subsequently evaluated the reliability of the
definitions and scoring for enthesitis in SpA and agreed
on an accepted definition that separates US features
into inflammatory (Doppler signal, hypoechogenicity,
thickened enthesis) and structural (calcifications/enthe-
sophytes and erosions at the enthesis) with each com-
ponent scored as either present/absent [7].
Heterogeneous definitions of US-detected pathologies
and scoring systems may affect the validity and general-
izability of results of US studies of enthesitis in PsA.
Thus it is important that studies adopt contemporary
standardized definitions, employ validated scoring sys-
tems and systematically describe US scanning proto-
cols. The EULAR recommendations for the reporting of
US studies in rheumatic and musculoskeletal diseases
(RMDs) [16] are the first to provide a checklist to aid the
reporting of US imaging in rheumatology research. The
checklist covers domains such as the blinding of sonog-
raphers, scanning acquisition and scoring, equipment
(e.g. US machine and transducer brand and model) and
equipment settings (conventional B-mode and Doppler).
Until these recommendations are widely implemented, it
is likely that study heterogeneity may limit the generaliz-
ability and clinical utility of findings. Evaluation of the
current literature with regards to the quality of the evi-
dence and reporting of US features of enthesitis in PsA
will provide a key point of reference whereby reports of
US pathology can be interpreted in the context of study
heterogeneity, which may help to inform development of
an optimum systematic approach to enthesitis manage-
ment with US in the future.
Accordingly, the primary aims of this systematic re-
view were to evaluate the methodological and reporting
quality of US studies of enthesitis at the Achilles tendon
in people with PsA, to identify the definitions and scor-
ing systems adopted and to estimate the prevalence of
US features of enthesitis in this population.
Methods
Review protocol
The Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) 2020 guideline were fol-
lowed throughout the review process (Supplementary
Table S1, available at Rheumatology Advances in
Practice online) [17].
Search strategy
Five electronic databases were searched [AMED,
CINAHL and MEDLINE (via EBSCO host); ProQuest
(Health and Medical Collection and Nursing and Allied
Health Database) and Web of Science core collection]
from conception of the study to 10 March 2021 and the
‘auto-alert’ function delivered weekly updates of any
subsequent publications until April 2021. Peer-reviewed
studies that included a reference to at least one of the
following were sought for inclusion: hypoechogenicity,
increased thickness of the tendon, erosions, bursitis,
calcifications, enthesophytes and Doppler signal
detected on US at the Achilles tendon in patients with
PsA. Key words and combinations specific to each
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database were used relating to PsA, Achilles tendon
enthesitis/pathology and US scoring (Table 1). The
search strategy, including a search of reference lists for
further eligible texts, was conducted by one reviewer
(A.P.).
Inclusion and exclusion criteria
All titles were screened and the subsequent abstracts
and full-text papers were reviewed (Supplementary Fig.
S1, available at Rheumatology Advances in Practice on-
line). Selected studies had to describe original research
findings, be published in the English language in a peer-
reviewed journal, assess adults 18 years of age and
describe US features of the Achilles tendon and/or the
Achilles entheses in a PsA population. Pharmacological
studies were included if they provided sufficient informa-
tion at baseline. Studies did not have to include a
healthy control group for comparison and no limit was
set on the date of publication. Studies that indicate only
the presence/absence of Achilles enthesitis were ex-
cluded. Review articles, case studies/reports, abstracts,
research papers involving non-human subjects and non-
English articles were excluded.
Assessment of methodological quality
Methodological quality was independently assessed
by two reviewers (A.P. and G.H.) and a modified ver-
sion of the Quality Index (QI) tool by Downs and Black
was used to assess the quality of studies (Table 2)
[18]. The 15 items that were included allowed for iden-
tification of methodological pitfalls including sampling
methods, use of valid and reliable outcome measures
and appropriate adjusting for confounding variables in
the statistical analysis. A modified version of Q10 was
TABLE 1 Search strategy
Articles, n
AMED (EBSCO host)
S1 ‘psoriatic arthritis’ OR PsA OR ‘psoriatic arthropath*’ OR spondyloarth* 152
S2 ‘achilles tend*’ OR ‘tendo achilles’ OR ‘achilles paraten*’ OR ‘calcaneal tendon’ OR ‘tendo calca-
neus’ OR ‘achilles enthes*’ OR ‘achilles insertion’ OR ‘achilles burs*’ OR ‘retrocalcaneal burs*’
1290
S3 ultrasound OR scan OR sonograph* OR ultrasonograph* OR US OR MSUS OR ‘power doppler’
OR PDUS OR ‘colour doppler’ OR ‘colour doppler’ or elastograph*
6424
S4 S1 AND S2 AND S3 3
CINAHL (EBSCO host)
S1 ‘psoriatic arthritis’ OR PsA OR ‘psoriatic arthropath*’ OR spondyloarth* 9396
S2 ‘achilles tend*’ OR ‘tendo achilles’ OR ‘achilles paraten*’ OR ‘calcaneal tendon’ OR ‘tendo calca-
neus’ OR ‘achilles enthes*’ OR ‘achilles insertion’ OR ‘achilles burs*’ OR ‘retrocalcaneal burs*’
4409
S3 ultrasound OR scan OR sonograph* OR ultrasonograph* OR US OR MSUS OR ‘power doppler’
OR PDUS OR ‘colour doppler’ OR ‘colour doppler’ or elastograph*
284 805
S4 S1 AND S2 AND S3 22
MEDLINE (EBSCO host)
S1 ‘psoriatic arthritis’ OR PsA OR ‘psoriatic arthropath*’ OR spondyloarth* 41 296
S2 ‘achilles tend*’ OR ‘tendo achilles’ OR ‘achilles paraten*’ OR ‘calcaneal tendon’ OR ‘tendo calca-
neus’ OR ‘achilles enthes*’ OR ‘achilles insertion’ OR ‘achilles burs*’ OR ‘retrocalcaneal burs*’
9143
S3 ultrasound OR scan OR sonograph* OR ultrasonograph* OR US OR MSUS OR ‘power doppler’
OR PDUS OR ‘colour doppler’ OR ‘colour doppler’ or elastograph*
1 033 146
S4 S1 AND S2 AND S3 67
ProQuest (Health and Medical Collection and Nursing and Allied Health Database)
S1 ‘psoriatic arthritis’ OR PsA OR ‘psoriatic arthropath*’ OR spondyloarth* 16 493
S2 ‘achilles tend*’ OR ‘tendo achilles’ OR ‘achilles paraten*’ OR ‘calcaneal tendon’ OR ‘tendo calca-
neus’ OR ‘achilles enthes*’ OR ‘achilles insertion’ OR ‘achilles burs*’ OR ‘retrocalcaneal burs*’
2726
S3 ultrasound OR scan OR sonograph* OR ultrasonograph* OR US OR MSUS OR ‘power doppler’
OR PDUS OR ‘colour doppler’ OR ‘colour doppler’ or elastograph*
702 600
S4 S1 AND S2 AND S3 61
Web of Science (Core Collection)
S1 TOPIC=(‘psoriatic arthritis’ OR PsA OR ‘psoriatic arthropath*’ OR spondyloarth*) 40 194
S2 TOPIC=(‘achilles tend*’ OR ‘tendo achilles’ OR ‘achilles paraten*’ OR ‘calcaneal tendon’ OR
‘tendo calcaneus’ OR ‘achilles enthes*’ OR ‘achilles insertion’ OR ‘achilles burs*’ OR ‘retrocal-
caneal burs*’)
8034
S3 TOPIC=(ultrasound OR scan OR sonograph* OR ultrasonograph* OR US OR MSUS OR ‘power
doppler’ OR PDUS OR ‘colour doppler’ OR ‘colour doppler’ OR elastograph*)
1 901 299
S4 S1 AND S2 AND S3 79
Total number of articles 232
Total number without duplicates 146
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incorporated from MacLehose et al. [19]. A binary
scoring of 1 for ‘yes’ or 0 for ‘unable to determine/no’
was applied to each item and studies were rated over-
all as high (>85%), moderate (60%) or low (<60%)
based on a previous study that utilized a similarly
modified Downs and Black QI criteria for assessing
the risk of bias [20].
Assessment of the US reporting protocol
During the development of this review the 2021 EULAR
recommendations for the reporting of US studies in
RMDs [16] were published. Although the EULAR recom-
mendations were not intended for scoring published
work, we believed it was important to incorporate
aspects of the new consensus-based checklist (specifi-
cally around scoring and measurement reporting) into
the review design in the absence of any validated scor-
ing criteria.
Data extraction
A standardized data extraction form was used to obtain in-
formation on the study design, participant characteristics,
description of the US machine and settings, imaging tech-
niques and the frequency and descriptions of Achilles ten-
don/entheses US characteristics. The use of scoring or
measurement tools and validation status were reported.
Descriptive analyses
Descriptive statistics, including means, S.D.s, medians,
ranges and interquartile ranges (IQRs) were used to
summarize prevalence estimates of US features.
Results
The database search identified 232 records to be
screened. Following the removal of duplicates and the
TABLE 2 Modified Downs and Black Quality Index checklist
1 Is the hypothesis/aim/objective of the study clearly described?
2 Are the main outcomes to be measured clearly described in the Introduction or Methods section?
If the main outcomes are first mentioned in the Results section, the question should be answered no. All primary out-
comes should be described for yes.
3 Are the characteristics of the patients included in the study clearly described?
In cohort studies and trials, inclusion and/or exclusion criteria should be given. In case–control studies, a case defini-
tion and the source for controls should be given. Single case studies must state the source of the patient.
5 Are the distributions of principal confounders in each group of subjects to be compared clearly described?
A list of principal confounders is provided. YES¼ age, severity.
6 Are the main findings of the study clearly described?
Simple outcome data (including denominators and numerators) should be reported for all major findings so that the
reader can check the major analyses and conclusions.
7 Does the study provide estimates of the random variability in the data for the main outcomes?
In non-normally distributed data the IQR of results should be reported. In normally distributed data the S.E., S.D. or CI
should be reported.
10 Have 95% CIs and/or actual P-values been reported for the main outcomes, except where the P-value is <0.001?
11 Were the subjects asked to participate in the study representative of the entire population from which they were
recruited?
The study must identify the source population for patients and describe how the patients were selected.
12 Were those subjects who were prepared to participate representative of the entire population from which they were
recruited?
The proportion of those asked who agreed should be stated.
16 If any of the results of the study were based on ‘data dredging’, was this made clear?
Any analyses that had not been planned at the outset of the study should be clearly indicated. Retrospective¼no,
prospective¼ yes.
18 Were the statistical tests used to assess the main outcomes appropriate?
The statistical techniques used must be appropriate to the data. If no tests were done, but would have been appropri-
ate to do¼no.
20 Were the main outcome measures used accurate (valid and reliable)?
Where outcome measures are clearly yes/no/UTD described, which refer to other work or that demonstrates the out-
come measures are accurate¼ yes. All primary outcomes valid and reliable for yes.
21 Were the patients in the cases and controls (case–control studies) recruited from the same population?
The question should be answered UTD for cohort and case–control studies where there is no information concerning
the source of patients.
22 Were study subjects in the cases and controls (case–control studies) recruited over the same period of time?
For a study that does not specify the time period over which patients were recruited, the question should be answered
as UTD.
25 Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?
In non-randomized studies, if the effect of the main confounders was not investigated or no adjustment was made in
the final analyses the question should be answered as no. If no significant difference between groups shown then
yes.
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screening of titles and abstracts, 20 papers were
deemed eligible for full-text screening (Supplementary
Fig. S1, available at Rheumatology Advances in Practice
online). Five papers did not meet the eligibility criteria
and were removed, thus 15 papers were included
(Table 3) [3, 10, 30–42]. The date of publication ranged
from 2000 [36] to 2020 [31, 34], with studies from Italy
[30, 32, 34, 36–38], Egypt [31, 33], the UK [35, 40],
Kuwait [3], Israel [42], Norway [10], China [41] and The
Netherlands [43].
A total of 832 participants with PsA (1664 Achilles
entheses) were assessed using US. The diagnosis of
PsA was mostly based on the 2006 Classification for
Psoriatic Arthritis (CASPAR) criteria [44], two studies [32,
36] published prior to 2006 used the Moll and Wright cri-
teria [45] and two studies did not explicitly state the di-
agnostic criteria [31, 39]. The sample sizes of PsA
patients were relatively small, ranging from 12 [31] to
141 [10]. Of the studies that reported a healthy control
group (n¼7), 183 healthy control participants were in-
cluded (99 females, 84 males; mean age 42.3 years) [30,
32, 35, 36, 39–41]. Two studies identified PsA patients
as a ‘control’ group (one as ‘inactive’ PsA and one com-
paring psoriasis to PsA) [3, 33]. The majority of studies
focussed exclusively on PsA [3, 10, 30, 35, 36, 38–40,
42]; however, other comparator groups included
patients with psoriasis [33, 41], FM [34, 37], SpA [31]
and other types of arthritis [32].
Quality assessment
One study was rated as high quality [10], nine as moder-
ate quality [3, 32, 34, 35, 37, 39–42] and five as low
quality [30,31, 33, 36, 38] (Fig. 1). Very few studies pro-
vided sufficient information on their sampling methods,
specifically the proportion of those asked who agreed to
take part (Q12), the time period over which participants
(and controls) were recruited (Q22) or the actual proba-
bility values for main outcome measures (Q10). The
quality index scores ranged from 7/15 (47%) to 13/15
(87%) with a median score of 9 (IQR 2.5).
US protocol reporting
Further details of US protocol reporting can be found in
Table 4 and Supplementary Table S2, available at
Rheumatology Advances in Practice online.
Measurements were performed by rheumatologists [10,
30, 34, 37, 41, 42], sonographers [35, 39] and radiolog-
ists [3, 38] and 10 studies reported blinding to the
results of the clinical examination or other imaging
results [30, 32–39, 41]. Levels of US proficiency de-
scribed included ‘expert’ [3, 36], ‘experienced’ [10, 30,
32, 37, 38, 41] or ‘trained’ [34, 35, 39]. Patient position-
ing was detailed in seven studies as patients lying prone
with their feet hanging off the examination table at 90
flexion [3, 10, 30, 34, 35, 39, 41]. Scanning in both longi-
tudinal and transverse planes was reported in 8/15 stud-
ies [3, 10, 32, 33, 35, 36, 38, 39]. All studies reported
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the type of transducer (multifrequency linear array).
Frequency settings in B-mode (greyscale) US were dis-
cussed in three studies [37, 38, 40] and colour and/or
power Doppler (PD) settings (e.g. pulse repetition fre-
quency) in nine studies [10, 30, 34, 35, 37–41].
Additional scanning procedures included adjusting the
room temperature for PD scanning [30, 41] and asking
patients to stop NSAIDs prior to examination [33, 34].
Prevalence and scoring of Achilles tendon/entheses
US features
When describing the prevalence of Achilles tendon/
entheseal pathology, 9/15 (60%) studies referred to the
absolute frequency and/or percentage of Achilles enthe-
ses (n¼ 1080 entheses) involved [3, 10, 30, 31, 34, 35,
37, 39, 41] and 6/19 (40%) studies only referred to the
absolute frequency and/or percentage of participants
(n¼292) affected [32, 33, 36, 38, 40, 42]. Of the studies
that reported the frequency and percentage of partici-
pants affected, four of six [32, 36, 38, 42] stated that the
Achilles entheses were scanned bilaterally and we de-
duced, based on the scoring system they adopted, that
the other two studies [33, 40] also scanned bilaterally.
Given the heterogeneity in reporting (entheses affected
vs participants affected), we have reported both sepa-
rately (Table 5).
US features according to the OMERACT 2018
consensus-based definition of enthesitis [7] include the
following:
. Hypoechogenicity was detected in 18/306 Achilles
entheses [mean 5.9% (S.D. 0.9)] in two of nine studies
[10, 31] and in 7/31 participants (33.3%) in one of six
studies [38].
. Increased thickness was detected in 228/936 Achilles
tendons [mean 22.1% (S.D. 12.2), median 17, range 4.2–
40.4, IQR 20.6] in seven of nine studies [3, 10, 30, 31,
34, 39, 41] and in 15/63 participants [mean 26.2% (S.D.
7.2)] in two of six studies [38, 40].
. Erosions at the site of the Achilles tendon insertion at
the posterior calcaneum were detected in 30/936
entheses [mean 3.3% (S.D. 2.5), median 2.9, range 0–
7.5, IQR 4.6] in seven of nine studies [3, 10, 30, 31, 34,
39, 41] and in 14/188 participants [mean 11.1% (S.D.
5.9), range 4.8–19) in three of six studies [32, 38, 40].
. Calcifications were detected in 191/406 entheses
[mean 42.6% (S.D. 15.6), range 25–63] in three of nine
studies [10, 31, 39] and in 13/21 (61.9%) participants in
one of six studies [38].
. Enthesophytes were detected in 343/812 entheses
[mean 41.3% (S.D. 15.6), median 53.8, range 18.6–56.7,
IQR 32.9] in five of nine studies [3, 10, 30, 34, 41] and in
36/63 participants [mean 58.4% (S.D. 3.6)] in two of six
studies [38, 40].
. Doppler signal at the site of insertion was detected in
109/929 entheses [mean 11.8% (S.D. 10.1), median 12,
range 0–29.5, IQR 18.8) in six of nine studies [10, 30,
31, 34, 39, 41] and in 4/63 participants [mean 8.4% (S.D.
5.9)] in two of six studies [38, 40].
There was significant variation in the methods of scor-
ing US features of enthesitis. Four studies used the
GUESS criteria [30, 34, 40, 41], 1 the MASEI [39] and 3
described non-validated semi-quantitative scoring [10,
35, 37] including Brown et al. [29], which was used in
RA for scoring B-mode and Doppler signal [35]. Doppler
signal was scored both as binary (present/absent) [30,
31, 41] and semi-quantitatively as per the five stages
described by D’Agostino et al. 2003 [31, 38] and three
stages outlined by D’Agostino et al. 2009 [30, 41].
US features in healthy controls
Five of the seven studies that assessed a healthy control
population reported the absolute frequency and/or per-
centage of Achilles entheses (N¼190 entheses) [30, 35,
39, 41] and two of seven reported the absolute fre-
quency and/or percentage of participants (N¼ 88 partici-
pants) [32, 36, 40]. Hypoechogenicity was not assessed
in healthy control participants. Increased thickness was
detected in 2/170 entheses [mean 1.7% (S.D. 2.4), range
0–2.5] in three studies [30, 39, 41] and in 0% of partici-
pants in one study [40]. Erosions were detected in 2/170
entheses [mean 1.3% (S.D. 1.9), range 0–4] in three stud-
ies [30, 39, 41] and in 0% of participants in two studies
FIG. 1 Quality assessment
Score: Y (yes)¼ 1, N (no) and UTD (unable to determine)¼0. Total score¼ 15. Green: high quality (>85%); yellow:
moderate quality (60%); red: low quality (<60%).
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[32, 40]. Calcifications were detected in 4/50 entheses
(8%) in one study [39]. Enthesophytes were reported in
3/120 entheses (mean 2.5%) in two studies [30, 41] and
in 9/29 participants (31%) in one study [40]. Finally, PD
signal at the Achilles enthesis was reported in 1/170
entheses [mean 0.7% (S.D. 0.9), range 0–2] in three stud-
ies [30, 39, 41] and in 0% of participants in one
study [40].
Discussion
The aims of this systematic review were to describe the
definitions and scoring of US features of Achilles enthe-
sitis in PsA, including assessment of the overall quality
of studies and evaluation of the quality of the reporting
of US protocols. Due to the heterogeneity observed in
the definitions, scoring methods and quality of studies, a
narrative and descriptive approach to the analysis and
synthesis of the results was adopted. All of the 15 stud-
ies referred to at least one US feature at the Achilles
tendon/entheses, but the lack of generalizability arising
from the variation in definition and scoring could sug-
gest the frequency and percentage of entheses/partici-
pants affected should be interpreted with caution. The
quality of reporting of US protocols and procedures was
not consistent across the studies and thus contributes
further to the lack of generalizability of results.
US technology has advanced considerably since the
early 2000s and this may account for some of the vari-
ability noted between the studies, as image acquisition
and interpretation has greatly improved. Despite the
technological advancement of US, our review has
highlighted the potential pitfalls of US definitions of
Achilles enthesitis in PsA. For example, tendon thicken-
ing as a result of a biomechanical tendinopathy will
appear the same on US as tendon thickening due to an
inflammatory enthesitis, yet will be histologically differ-
ent. Whether Achilles enthesitis in PsA is a biomechani-
cal stress-induced inflammation of the entheseal tissues
or an inflammatory-induced tendinopathy is still un-
known [1, 46].
The majority of the studies were scored as low [30,
31, 33, 36, 38] or moderate quality [3, 32, 34, 35, 37,
39–42], with only one paper scoring high [10] based on
the modified version of the Downs and Black QI criteria.
Most studies were marked down based on their descrip-
tion of sampling methods. Additionally, very few studies
adjusted for potential confounders in the analysis of
results, which is now partly addressed in the EULAR
recommendations under the reporting of ‘contextual fac-
tors’ (e.g. exercise, alcohol, caffeine and smoking) [16].
The identification of contextual factors was not widely
reported in the studies included. Two studies [30, 41]
reported adjusting the room temperature to 20C for the
assessment of Doppler US with reference to D’Agostino
et al. [22], however, there is no substantial evidence to
suggest there is any effect. One study asked patients to
refrain from taking NSAIDs 3 weeks prior to examination
[33] and another 24 hours prior to examination [34].
There is evidence to suggest that NSAID use could
mask both B-mode features and PD signal and ulti-
mately result in a better US score [47].
Scoring of US features varied between the studies
with four using the GUESS scoring criteria, one using
the MASEI and the rest either scoring features as
TABLE 5 Quantiles and point prevalence of US features of Achilles enthesitis in people with PsA
Ultrasound feature Studies (/15), n Point-prevalence
of US feature,
n/N (%)
Quantiles Mean S.D. IQR
25% Median 75%
Studies reporting no. of
entheses (entheses
assessed¼1080)
9 [3, 10, 30, 31, 34, 35, 37, 39, 41]
Hypoechogenicity 2 [10, 31] 18/306 (5.9) 5.1 5.1 0.9
Increased thickness 7 [3, 10, 30, 31, 34, 39, 41] 228/936 (24.4) 13.1 17.0 33.7 22.1 12.2 20.6
Erosion(s) 7 [3, 10, 30, 31, 34, 39, 41] 30/936 (3.2) 1.4 2.9 6 3.3 2.5 4.6
Calcification(s) 3 [10, 31, 39] 191/406 (47.0) 39.7 42.6 15.6
Enthesophytes 5 [3, 10, 30, 34, 41] 343/812 (42.2) 22.9 53.8 55.9 41.3 15.6 32.9
Doppler signal 6 [10, 30, 31, 34, 39, 41] 106/929 (11.4) 1 12 16.3 11.8 10.1 18.8
Studies reporting no. of
subjects (no. of partici-
pants assessed¼292)
6 [32, 33, 36, 38, 40, 42]
Hypoechogenicity 1 [38] 7/31 (33.3)
Increased thickness 2 [38, 40] 15/63 (23.8) 26.2 26.2 7.2
Erosion(s) 3 [32, 38, 40] 14/188 (7.4) 9.5 11.1 5.9
Calcification(s) 1 [38] 13/21 (61.9)
Enthesophytes 2 [38, 40] 36/63 (57.1) 58.4 58.4 3.6
Doppler signal 2 [38, 40] 4/63 (6.3) 8.4 8.4 5.9
The data in this table detail summary statistics using percentages of entheses/participants in each study.
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present/absent, using non-validated semi-quantitative
scoring (score 0–3) or not scoring US features at all.
Doppler US was scored separately in three studies, ei-
ther from 0–3 or 0–5, and they all referred to D’Agostino
et al. [21, 22]. Similarly, the definitions of US features
were not consistent throughout the studies (Table 3),
with the GUESS, MASEI and variations of the
OMERACT US Task Force recommendations being
used irrespective of the date of publication. Although
there are similarities between the definitions, the results
are not entirely comparable. With the ever-evolving tech-
nological advances of point-of-care US and the increase
in accessibility and uptake by clinicians (with varying
levels of US training and experience), it is even more im-
perative to have clear definitions and a widely accepted
validated scoring criteria that is appropriate for both
clinical practice and research.
We observed substantial variation in the prevalence fig-
ures for features of enthesitis at the Achilles tendon, but
due to heterogeneity, it is unclear whether the variation
can be explained by protocol variations or sample charac-
teristics such as disease duration/severity. Only 5/15
studies specifically recruited newly diagnosed (<2 years)
PsA patients, and reported prevalence figures were
similar between these studies and those with a longer
disease duration. Prevalence estimates should be inter-
preted with caution, as included studies mostly adopted
non-probability sampling largely involving consecutive
recruiting of outpatients and so may be vulnerable
to bias.
The potential implications for standardizing the use of
validated definitions and scoring systems for assessing
the Achilles tendon in PsA and clear US protocol report-
ing are significant. First, it will allow us to better under-
stand the prevalence of US features of pathology and
levels of severity of symptoms associated with Achilles
entheseal and tendon disease. This information could
then be used to aid the stratification of treatment, partic-
ularly non-medical management, based on the severity
and/or type of pathology present. The grouping of US
features into structural and inflammatory components in
the most recent OMERACT guidance [8] could be used
as a starting point to tailor treatment accordingly. The
current provision and efficacy of non-medical manage-
ment of Achilles enthesitis in PsA has not been
researched, and based on this lack of evidence, care
provision will likely vary considerably. Another clinical
consideration for management is the overlap of a PsA
disease-driven enthesitis at the Achilles and biomechan-
ically driven Achilles tendinopathy. Although Achilles
tendinopathy in healthy people is typically found at the
mid-portion of the tendon, it can also be detected at the
insertion [48]. The US criteria for staging Achilles tendin-
opathy in healthy populations (based on the continuum
model of tendon pathology) has a number of similarities
with the US definition of enthesitis in PsA (e.g. altered
echotexture, thickening and the presence of vascularity)
[49]. It is also worth noting that US features of Achilles
enthesitis can also be detected in healthy individuals,
particularly the presence of enthesophytes and tendon
thickening [50].
This systematic review has some limitations that merit
attention. The EULAR 2021 recommendations were not
intended for use as a scoring checklist for published re-
search but were used as guidance in the absence of a
suitable alternative. A number of papers were excluded
based on their reporting of the simple presence/absence
of Achilles enthesitis only, as we specifically wanted to
identify the description, scoring and prevalence of these
US features. As such, the number of papers included in
this study was small (n¼15) relative to the body of liter-
ature that has assessed for simple presence/absence of
Achilles enthesitis in PsA.
Recommendations for future research include the de-
velopment of a validated checklist or scoring system to
assess the quality of US studies in rheumatology. There
may be future potential for evaluating the effectiveness
of tailoring medical and non-medical management
approaches based on the presence and/or severity of
certain US features at the Achilles tendon/entheses in
PsA to improve symptoms. There is a paucity of evi-
dence for the non-medical management of Achilles
enthesitis and enthesopathy in PsA and at present the
management is similar regardless of whether structural
and/or inflammatory features are present [5]. There may
be scope for the phenotyping of PsA-driven enthesitis
based on clinical characteristics and US-detected
pathologies.
Recommendations for authors of future studies
reporting Achilles tendon/entheses features in PsA in-
clude using the most up-to-date, reliable definitions
and scoring for US features (currently Balint et al. [7]),
report both the number of entheses and the number
of participants affected to allow for synthesis of
results and use the 2021 EULAR recommendations
[16] as a guide for reporting US protocols and
procedures.
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